WHY IS THIS STUDY IMPORTANT?

- Treatment for acromegaly aims to lower certain hormones – insulin-like growth factor 1 (IGF-1) and growth hormone (GH) – in the body and also reduce symptoms of acromegaly.
- When surgery, which is the usual first-line treatment, fails, medical treatment in the form of an injectable is often used.
- To our knowledge, paltusotine is the first nonpeptide, once-daily oral somatostatin agonist being evaluated for the treatment of acromegaly.
- For patients looking for an alternative to injections or twice-daily orals, paltusotine may reduce the burden of acromegaly treatment. Additionally, it may allow your doctor to determine an optimized dosing regimen more quickly compared with existing therapies.

Romina, diagnosed with acromegaly in 2016

Mike, diagnosed with acromegaly in 2016

STUDY PARTICIPATION IS VOLUNTARY

By contacting us, you are not obligated to take part in the study nor complete the study if you would decide to participate.

Study code: CRN00808-08
Study Sponsor:
Crinetics Pharmaceuticals, Inc.

V1-06OCT2021

ACROMEGALY TREATMENT 24 HOURS 1 DOSE



Louis, diagnosed with acromegaly in 2020

A clinical study for an investigational *ORAL, ONCE-DAILY* acromegaly treatment is looking for participants.

pathfndr2

ABOUT THE STUDY

The purpose of this study is to see if the Sponsor's investigational medication, paltusotine, is safe and effective in controlling the IGF-1 levels in patients with acromegaly.

ABOUT ACROMEGALY

Acromegaly is a hormonal disorder that results from too much growth hormone (GH) in the body. GH is produced by a small gland in the brain called the pituitary gland. Usually, the GH excess comes from benign (noncancerous) tumors of the pituitary. The benign pituitary tumor that causes acromegaly makes too much GH and it affects your body by promoting abnormal growth of the bones of the hands, feet, face, jaw and soft tissues. These high GH levels can lead to a wide range of cardiovascular (heart and blood vessels issues, e.g. high blood pressure), respiratory (lungs), endocrine (hormone) and metabolic (e.g. diabetes – elevated blood sugar) illnesses, as well as joint pain, weakness, and sometimes visual disturbances.



VISIT THE TRIAL PAGE ON CLINICALTRIALS.GOV

Review the study summary, outcome measures, inclusion/exclusion criteria and more for the Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2).

INTERESTED PARTICIPANTS MUST:

- Be 18 years of age or older
- Have confirmed-active acromegaly

INTERESTED PARTICIPANTS MAY RECEIVE:

- Study-related care and study medication at no cost
- Reimbursement for travel

WHAT ELSE DO I NEED TO CONSIDER?

- This is a Phase 3 clinical study testing an investigational medication.
- This study will include 3 groups of patients:
  - Those who have *not* been previously treated with acromegaly medications (medically naïve)
  - Those who have *previously* taken acromegaly medications but have not taken them for some time
  - Those *currently* taking acromegaly medications and willing to discontinue for a period of time
- The study team can explain the possible benefits and risks of participating in this study.
- You do not have to take part in this study. If you decide to participate in this trial, you can choose to discontinue your involvement at any time.
- A team of medical professionals will monitor your acromegaly and your overall health throughout the study.

WHAT WILL THE STUDY INVOLVE?

The Screening Period may vary from 2-16 weeks depending on which of the 3 groups the subject comes from. After the Screening Period, subjects will be enrolled in a 24-week Treatment Period with approximately 10 planned visits.

Subjects will be divided by chance in a 1:1 ratio to receive either paltusotine or placebo (placebo tablets will look identical to the paltusotine tablets but not contain paltusotine or any other study medication).

At the end of the Treatment Period, subjects who in the opinion of the investigator may benefit from treatment with paltusotine, may be enrolled in a long-term, open label extension (OLE) for up to 100 weeks. During the OLE, all subjects will receive paltusotine.

Mike with his supportive wife Jackie